

AMENDMENTS

Amendments to the Specification:

Page 1, following the title, first paragraph, amend to read as follows:

This is a Continuation of U. S. Serial No. 09/529,121, filed June 13, 2000, which is a National Phase Application of PCT/US98/19794, filed 09/22/98, which claims the benefit of U.S. Provisional Application No. 60/061,589, filed 10/10/97.

Amendments to the Claims:

1. (Currently amended) A peptide comprising an agonist of a MHC Class I binding native sequence:

YLSGANLNL (Seq. ID No: 1)
| |
1 2 3 4 5 6 7 8 9

wherein the agonist has ~~at least one~~ an amino acid substitution at any of positions 1, 3, 4, 5, 6, 7, and 8 ~~a non-MHC anchor position of SEQ ID NO:1~~ and said agonist has enhanced immunogenicity compared to the native sequence.

2. (Previously presented) The peptide according to claim 1 wherein the agonist varies in an amino acid substitution at position 6 from Seq. ID No: 1.
3. (Previously presented) The peptide according to claim 1 wherein the agonist varies in an amino acid substitution at position 7 from Seq. ID No: 1.
4. (Previously presented) The peptide according to claim 1 wherein the agonist varies in an amino acid substitution at position 6 and position 7 from Seq. ID No: 1.
5. (Previously presented) The peptide according to claim 1 comprising an amino acid sequence selected from the group consisting of: YLSGADLNL (Seq. ID No: 2), YLSGADINL (Seq. ID No: 3), YLSGANINL (Seq. ID No: 4), YLSGACLNL (Seq. ID No: 5), and combinations thereof.